Special CommunicationTransarterial Treatment of Colorectal Cancer Liver Metastases with Irinotecan-Loaded Drug-Eluting Beads: Technical Recommendations

Add time:09/10/2019    Source:sciencedirect.com

Transcatheter hepatic arterial administration of irinotecan-loaded drug-eluting beads (DEBIRI) is used to treat liver-only or liver-dominant metastatic disease from colorectal cancer (CRC). Eligibility for DEBIRI should be established in each individual patient by a multidisciplinary team based on comprehensive clinical, imaging, and laboratory assessment. Standardization of DEBIRI technique and protocols would be expected to lead to improved efficacy and safety. The present article provides a set of technical recommendations for the use of DEBIRI in the treatment of hepatic CRC metastases.

We also recommend Trading Suppliers and Manufacturers of Irinotecan hydrochloride trihydrate (cas 136572-09-3). Pls Click Website Link as below: cas 136572-09-3 suppliers

Prev:Genotoxic effects of irinotecan combined with the novel platinum(II) complexes in human cancer cells
Next:Design and synthesis of glycosidase inhibitor 5-amino-1,2,3,4-cyclohexanetetrol derivatives from (−)-vibo-quercitol☆)